Sucampo Pharmaceuticals, Inc.
4520 East-West Highway
Suite 300
Bethesda,
MD 20814
United States - Map
Phone: 301-961-3400
Fax: 301-961-3440
Web Site: http://www.sucampo.com
| Sucampo Pharmaceuticals, Inc., through its subsidiaries, focuses on the discovery, development, and commercialization of drugs based on prostones in the United States, Europe, and Japan. It offers prostone-based compounds for the treatment of gastrointestinal, vascular, respiratory, and central nervous system diseases and disorders. The company primarily markets Amitiza for the treatment of chronic idiopathic constipation in adults, as well as for irritable bowel syndrome with constipation in adult women. It also offers Rescula (unoprostone isopropyl) for the treatment of glaucoma. In addition, Sucampo Pharmaceuticals is conducting two Phase III pivotal trials of Amitiza for opioid-induced bowel dysfunction; a Phase II proof of concept trial of Cobiprostone for the prevention of non-steroidal anti-inflammatory drug induced ulcers; various preclinical trials of Cobiprostone for cystic fibrosis respiratory symptoms, topical ulcers and wounds, and chronic obstructive pulmonary disease; and a preclinical phase study of SPI-017 for Alzheimers disease. The company also has various pre-clinical studies of six additional preclinical prostone compounds, including two combination candidates for age-related diseases. Sucampo Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Ryuji Ueno M.D., Ph.D., Ph.D., 55
Co-Founder, Chairman, Chief Exec. Officer, Pres and Chief Scientific Officer |
$
747.00K | N/A | Mr. Jan Smilek , 42
Chief Financial Officer, Chief Accounting Officer, VP of Fin. and Corp. Controller |
$
251.00K | N/A | Mr. Stanley G. Miele , 44
Pres of Sucampo Pharma Americas Inc |
$
251.00K | N/A | Dr. Gayle Dolecek P.D., M.P.H.,
Sr. VP of R&D |
$
255.00K | N/A | Ms. Mariam E. Morris CPA, 41
Consultant |
$
201.00K |
$
14.00K |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.51% Nasdaq 
0.23 (5.49%) 
Profile
